Scynexis (SCYX) Net Equity Issued and Repurchased (2016 - 2025)
Scynexis (SCYX) posted Net Equity Issued and Repurchased of $1000.0 for Q4 2025, up 125.0% on a QoQ basis from -$4000.0 in Q3 2023.
Scynexis (SCYX) Net Equity Issued and Repurchased (2016 - 2025) Analysis & Trends
Scynexis' Net Equity Issued and Repurchased history runs 9 years deep, the most recent figure standing at $1000.0 for Q4 2025.
- Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $1000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3000.0 (changed N/A YoY) and the FY2025 annual result came in at $5000.0, changed N/A from the prior year.
- Net Equity Issued and Repurchased was $1000.0 for Q4 2025 at Scynexis, up from -$4000.0 in the prior quarter.
- Across five years, Net Equity Issued and Repurchased topped out at $30.5 million in Q4 2021 and bottomed at -$4000.0 in Q3 2023.
- A 4-year average of $4.2 million and a median of $216968.5 in 2021 frame the typical range for Net Equity Issued and Repurchased.
- Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased sank 44.34% — and 2023, when it slumped 104.0%.
- Scynexis' Net Equity Issued and Repurchased stood at $30.5 million in 2021, then tumbled by 99.67% to $100000.0 in 2022, then slumped by 104.0% to -$4000.0 in 2023, then surged by 125.0% to $1000.0 in 2025.
- Business Quant data shows SCYX's Net Equity Issued and Repurchased at $1000.0 in Q4 2025, -$4000.0 in Q3 2023, and $4000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Jun 30, 2023 | 4,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 2.16 Mn |
| Mar 31, 2022 | 2.16 Mn |
| Dec 31, 2021 | 30.53 Mn |
| Dec 31, 2021 | 30.53 Mn |
| Sep 30, 2021 | 333,937.00 |
| Sep 30, 2021 | 333,937.00 |
| Jun 30, 2021 | 800,000.00 |
| Jun 30, 2021 | 800,000.00 |
| Dec 31, 2020 | 85.85 Mn |
| Dec 31, 2020 | 85.85 Mn |
| Sep 30, 2020 | 600,000.00 |
| Sep 30, 2020 | 600,000.00 |